en پژوهشی اصيل Original Research <span style="font-size:10pt"><span style="text-autospace:none"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span cambria="" style="font-family:">Aims</span></b><span cambria="" lang="EN-GB" style="font-family:">: Stevens-Johnson syndrome and toxic epidermal necrolysis are serious severe cutaneous adverse reactions with high mortality and morbidity induced by medications. In this cross sectional study, we investigated, suspected drugs, and potential treatments of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. </span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span cambria="" lang="EN-GB" style="font-family:">Methods:</span></b><span cambria="" lang="EN-GB" style="font-family:"> A cross- sectional descriptive study was conducted on 60 patients admitted with a diagnosis of Stevens-Johnson Syndrome (47 patients) or Toxic Epidermal Necrolysis (13 patients). Except for the therapeutic procedure, data related to pharmacological causes and treatment was obtained from electronic medical records. They were treated daily with either co-administration of intravenous immunoglobulin (1-2mg/kg) and corticosteroid (Prednisolone Forte 1-2mg/kg; maximum 60mg/kg) or exclusive corticosteroid.</span></span></span></span><br> <span style="font-size:10pt"><span style="text-autospace:none"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span cambria="" style="font-family:">Finding</span></b><b><span cambria="" lang="EN-GB" style="font-family:">:</span></b><span cambria="" lang="EN-GB" style="font-family:"> Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis were more frequent among females (56.7%) and young people (73.4%). Sepsis was observed in 11.8% of Stevens-Johnson Syndrome patients treated with intravenous immunoglobulin and corticosteroid (mean hospitalization days 2.2&plusmn;0.6) but not in those who were treated with a corticosteroid (mean hospitalization days 1.6&plusmn;0.5 days), though all Stevens-Johnson Syndrome patients improved after treatment. In Toxic Epidermal Necrolysis patients, 76.9% of the them showed sepsis that received intravenous immunoglobulin and corticosteroid. The mortality rate was 5%. <a name="_Hlk97849144">Antibiotics and anticonvulsant drugs </a>were found to be the main causes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. </span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span cambria="" lang="EN-GB" style="font-family:">Conclusion:</span></b><span cambria="" lang="EN-GB" style="font-family:"> Either intravenous immunoglobulin and corticosteroid or corticosteroid treatments seem to be effective for Stevens-Johnson Syndrome improvement. </span><span cambria="" style="font-family:">Potential drug Causes of </span><span cambria="" lang="EN-GB" style="font-family:">Stevens-Johnson Syndrome</span><span cambria="" style="font-family:"> and </span><span cambria="" lang="EN-GB" style="font-family:">Toxic Epidermal Necrolysis</span> <span cambria="" style="font-family:">included </span><span cambria="" lang="EN-GB" style="font-family:">Antibiotics and anticonvulsant drugs. </span></span></span></span><br> <br> <span style="font-size:11pt"><span style="line-height:150%"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span style="line-height:150%"><span style="font-family:"Times New Roman","serif""></span></span></span></b></span></span></span> Anticonvulsants,Adrenal Cortex Hormones,IVIG,Phenobarbitals,Lyell's Syndrome, 19 26 http://jccs.yums.ac.ir/browse.php?a_code=A-10-150-1&slc_lang=en&sid=1 S. Zareei 10031947532846005653 10031947532846005653 No Department of Biochemistry, School of Medicine, Kharazmi University, Tehran, Iran S.H. Nabavizadeh 10031947532846005654 10031947532846005654 No Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran N. Zareei 10031947532846005655 10031947532846005655 No Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran R. Abbasi abbasir86@yahoo.com 10031947532846005656 10031947532846005656 Yes Department of Pediatric, School of Medicine, Yasuj University of Medical Science, Yasuj, Iran